USFDA
-
November 23, 2021, Tuesday
Alembic Pharma gets USFDA nod for formoterol fumarate inhalation solution
Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US Food & Drug Administration (USFDA) for its ...
-
November 18, 2021, Thursday
Zydus Cadila gets USFDA nod for cancer drug with 180-days exclusivity
The company has received approval from the US Food and Drug Administration (USFDA) for the Nelarabine injection 250 MG/50ML, a ...
-
November 07, 2021, Sunday
Leading drug makers Sun Pharma, Lupin recall products in US market
According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."
-
October 21, 2021, Thursday
Biocon's insulin biosimilar Glargine gets preference in top US formulary
The USFDA had approved biosimilar Insulin Glargine-yfgn injection (Semglee) as the first interchangeable biosimilar product in ...
-
October 08, 2021, Friday
Gland Pharma gets tentative nod from USFDA for generic Sugammadex injection
Drug firm Gland Pharma on Friday said it has received a tentative nod from the US health regulator for generic Sugammadex ...
-
October 08, 2021, Friday
Zydus Cadila gets tentative nod from USFDA to market generic acne drug
Drug firm Zydus Cadila on Friday said it has received tentative nod from the US health regulator to market generic Adapalene and ...
-
October 06, 2021, Wednesday
Lupin gets tentative nod from USFDA to market generic Brexpiprazole tablets
The product is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets in the same strengths
-
September 24, 2021, Friday
US FDA okays Covid booster shot for people above 65, or at high-risk
The US Food and Drug Administration (FDA) has authorised booster shots of the Pfizer Covid-19 vaccine for people aged 65 and ...
-
September 21, 2021, Tuesday
Glenmark Pharma gets USFDA nod for generic antibiotic cream
Glenmark Pharma said it has received approval from the US health regulator to market Clindamycin Phosphate Foam, an antibiotic ...
-
September 20, 2021, Monday
Lupin's underperformance may continue on US-driven regulatory challenges
US sales trajectory, margins key triggers over the next couple of quarters
